Posted by Michael Wonder on 10 Apr 2019
Canada needs to read the fine print on pharma costs
10 April 2019 - The proposed federal price controls for patented medicines will send the wrong signal to Canadian and global capital, meaning that companies will simply take their investments elsewhere.
As the old saying goes, when a deal seems too good to be true, it may very well be. It’s always important to read the fine print and understand what you’re signing up for, and this is something that Canadians need to be aware of when it comes to the federal government’s proposed approach to lowering pharmaceutical prices.
In 2017, the federal government developed a proposal to lower medication prices for Canadians by introducing changes to how the federal drug pricing watchdog, the Patented Medicine Prices Review Board (PMPRB), interprets excessive prices.
